Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival

Sequential intra-arterial infusion of 90Y-resin microspheres and mitomycin C in chemo refractory liver metastatic breast cancer patients: a single centre pilot study

“…6 In our institute MMC infusions are performed for almost 20 years for chemo refractory LMBC whereby a disease control of 58% is obtained with low grade adverse events. 9 In the present study we investigated whether MMC infusion is feasible and safe after 90 Y SIRT.…”

“…During the regular MMC protocol of our institute, patients can receive a maximum of 72 mg in 6 cycles whereby close monitoring is performed to adjust, postpone or stop the MMC infusion after each cycle. 9 In current study, the same protocol was followed in the last cohort, subsequently 4 patients did not receive all 6 MMC cycles. Thus, this pilot shows that the regular protocol of MMC can be followed after prior treatment with 90 Y.…”

“…10,11,[18][19][20] The median OS was higher compared to earlier studies where patients received only MMC infusion (12.6 versus 7.6 months). 9,14 However, the inclusion criteria for this study were more strict than our routine indications for MMC infusion. Consequently, patients had less extensive local and extra hepatic disease with a better performance status compared to our previous reported cohort of patients treated with MMC infusion only.…”

“…6 Several intra-arterial therapies have been applied for LMBC patients, such as radioembolization (Yttrium-90 ( 90 Y) resin microspheres), chemo embolization and chemo infusion, reported as effective and safe treatment options. [7][8][9] Of these treatments, the best results are reported for intraarterial radioembolization, with a disease control rate of 72-91% and an overall survival of 6.6-13.6 months. 7,[10][11][12] For over 15 years, LMBC patients are treated by intra-arterial chemo infusion with mitomycin C (MMC) in our institute whereby disease control is obtained in 58% with low adverse events in a very heavily pre-treated cohort.…”

“…7,[10][11][12] For over 15 years, LMBC patients are treated by intra-arterial chemo infusion with mitomycin C (MMC) in our institute whereby disease control is obtained in 58% with low adverse events in a very heavily pre-treated cohort. 9 Since primary breast cancer is sensitive for both systemic chemotherapy and external beam radiation therapy, LMBC patients might also benefit from the combined treatment of chemo infusion and selective internal radiation therapy (SIRT).…”